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Abstract
Background: Polycystic ovary syndrome is a common cause of chronic anovulation and infertility in otherwise
healthy fertile couples. Clomiphene citrate is used as a first-line ovulation induction therapy in patients with
polycystic ovary syndrome. Clomiphene citrate can cause both systemic and ocular side effects. We report a rare
side effect of illusory palinopsias in a patient with polycystic ovary syndrome treated with ovulation induction
therapy with clomiphene citrate, and emphasize the need for gynecologists and their patients to be aware of this
rare ocular side effect.
Case presentation: A 30-year-old Asian woman complained of persistent visual afterimages following treatment
with 100 mg clomiphene citrate for anovulation. Her symptoms started on the fourth day after commencing the
treatment and would last for 5 to 10 minutes. Similar visual symptoms were noted during her second cycle of
treatment with clomiphene citrate. The severity of her symptoms reduced following the stoppage of the
medication; however, the symptoms have persisted for more than 1 year since she stopped taking the drug.
Conclusions: Clomiphene citrate can cause disturbing illusory palinopsias. These afterimages persist even after
stopping the infertility medication. It is a side effect not frequently seen by gynecologists or ophthalmologists.
Gynecologists should make their patients aware of this rare ocular side effect when their patients start treatment
with clomiphene citrate for infertility.
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Background
Clomiphene citrate (CC) is a common selective estrogen
receptor modulator (SERM) used in ovulation induction
therapy in patients with polycystic ovary syndrome
(PCOS) that usually results in chronic anovulation [1].
We report a case of illusory palinopsias with CC in a pa-
tient with PCOS and emphasize the need for the gyne-
cologists to make their patients aware of this rare ocular
side effect of the drug.
Case presentation
A 30-year-old Asian woman diagnosed as having PCOS
underwent ovulation induction therapy with CC 100 mg
tablet daily for 5 consecutive days from day 5 to 9 of her
menstrual cycle. On the fourth day of commencing the
treatment, she developed visual disturbances and character-
istically described them as noting same color afterimages of
non-illuminated objects, shadow of a person moving in
front of her, some kind of flash on moving from a poorly
illuminated zone to a strongly illuminated zone, and some
waves in vision in broad daylight. The symptoms would
occur five to seven times in a month. The duration of these
visual symptoms would last for approximately 5 to 10
minutes. Her symptoms would gradually reduce after she
completed her treatment course for 5 days. Her symptoms
were not accompanied by other ocular symptoms such as
pain, redness, photophobia, or decrease in vision. She gave
no past or family history of migraine. A second course with
ovulation induction therapy again with 100 mg CC was
prescribed to her in the following month. She developed
similar visual symptoms 4 days after starting the treatment.
She conceived after taking two cycles of CC. One year
post-delivery, she visited an ophthalmologist at a tertiary
eye hospital with complaints of persistence of symptoms;
although the severity and frequency of symptoms were
much less than when she was under treatment with CC.
On ophthalmic examination, her best-corrected visual
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acuity in both eyes was 6/6, N6. Anterior and posterior
segment examinations of both eyes were normal. Brain
magnetic resonance imaging (MRI) was normal. A probable
diagnosis of CC-induced illusory palinopsia was made. She
was counseled regarding her condition and was asked to
follow-up at a regular interval of every 6 months.
Discussion
Palinopsia is a visual disturbance characterized by a persist-
ent recurrence of a visual image after the stimulus has been
withdrawn. Palinopsia is broadly grouped into two categor-
ies: illusory palinopsias and hallucinatory palinopsias [2].
Hallucinatory palinopsias are due to posterior cortical
lesions. The afterimages described are formed, long-lasting,
and high resolution. Illusory palinopsias are caused by
migraines, head trauma, prescription drugs, or hallucinogen
persisting perception disorder. In illusory palinopsias, the
afterimages described are affected by ambient light and
motion and are unformed, indistinct, or low resolution. In
our case, the patient noted positive afterimages which were
indistinct, poorly formed, and low resolution. These symp-
toms were very similar to that described in illusory palinop-
sias. An MRI of her brain did not show any neurological
lesions. Her visual symptoms were not followed by
migraine-like headache. Hence, the symptoms described
are classical of illusory palinopsias. Illusory palinopsias are
caused by diffuse neuronal pathology such as global alter-
ations in neurotransmitter receptors. CC, a SERM, is used
as the first line of therapy for pharmacological ovulation in-
duction. CC is characterized by agonistic properties when
endogenous estrogen levels are low, and acts as a competi-
tive antagonist when levels are high. Depletion of estrogen
receptors in the hypothalamus results in normalization of
gonadotropin-releasing hormone secretion, leading to
optimization of secretion of pituitary follicle-stimulating
hormone and hence follicular development and ovulation
[3]. Yilmaz et al. [4] have shown different patterns of
visually evoked potential latencies during different phases
of the menstrual cycle. The latencies are reduced during
the follicular and ovulatory phase of the menstrual cycle
whereas they are increased during the ovulatory phase of
the cycle [4]. Estrogen inhibits the synthesis of gamma-
aminobutyric acid, an important inhibitor neurotransmitter
in the cerebral and visual cortexes, and is involved in the
genesis of visually evoked potentials. The inhibition of
gamma-aminobutyric acid reportedly increases the excita-
tory effect on the striate cortex [5]. Thus, estrogen can
directly or indirectly stimulate the visual cortex, thus
triggering the development of visual hallucinations. CC
causes ocular side effects such as central retinal vein occlu-
sion, irreversible palinopsias, optic neuropathy, anterior
uveitis, and maculopathy [6–10]. Purvin [7] described visual
hallucinations in three women treated for infertility with
CC for 4 to 15 months. Despite stopping treatment, these
women remained symptomatic for a prolonged period of
time. In our case, the symptoms occurred with the intake
of the drug in the first month. The symptoms started as
early as 4 days following treatment and have persisted for
more than 1 year following the cessation of the drug. How-
ever, the frequency and severity of symptoms reduced after
stopping the drug. We believe that the visual symptoms
described by our patient were secondary to the use of CC.
Conclusions
To conclude, CC can cause disturbing visual palinopsias
and afterimages. Although previously reported, this case
describes a rare ocular side effect caused by CC, not fre-
quently seen either by ophthalmologists or gynecologists.
Gynecologists and/or infertility experts should educate
their patients regarding these possible ocular symptoms.
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